The treatment of brain tumors is complex and highly heterogeneous. All stages of the disease may occur in the same injury, with the spread of transitions between regions of pathological tissue (i.e., active tumor, necrosis, and meninges). Traditional MRI methods, although able to image brain tissue noninvasively, provide clinical information on the localization and characterization of lesions. However, the current reliance on the physician’s naked eye to identify tumor tissue in MRI images is time-consuming and inefficient and relies heavily on physicians experienced in diagnostic imaging. Therefore, the use of more diversified and advanced technologies to improve the efficiency of brain tumor identification and the accuracy of lesion segmentation has a high clinical application value.
We have a standardized process and quality control system for the large-scale production of high-throughput tissue microarrays. We can effectively utilize hundreds or thousands of tissue specimens at a time, either naturally or in the pathological state of brain tumors, to help you investigate the relationship between specific genes and the proteins they express and brain tumors. This can be useful for molecular diagnosis of brain tumors, localization of prognostic indicators and therapeutic targets, and screening antibodies and drugs.
Most of the accurate molecular pathology information of tumors comes from stereotactic biopsies, but the anatomical location of the brain makes tissue biopsy extremely risky, and the slightest mistake can bring unpredictable consequences to patients.